BioCentury
ARTICLE | Company News

Millennium, Trigen Holdings AG deal

January 29, 2007 8:00 AM UTC

Trigen received exclusive worldwide rights to develop and commercialize MLNM's IP covering glycoprotein VI ( GPVI), a platelet collagen receptor involved in thrombosis. Trigen expects to complete Phas...